Stockscreener 앱 받기
1.33
11.76%
0.14
시간 외 거래:
1.31
-0.02
-1.50%
전일 마감가:
$1.19
열려 있는:
$1.21
하루 거래량:
135.18K
Relative Volume:
0.18
시가총액:
$5.35M
수익:
-
순이익/손실:
$-7.10M
주가수익비율:
-0.2507
EPS:
-5.3059
순현금흐름:
$-8.30M
1주 성능:
+11.76%
1개월 성능:
+11.76%
6개월 성능:
-42.17%
1년 성능:
-81.20%
1일 변동 폭
$1.20
$1.37
1주일 범위
$1.17
$1.37
52주 변동 폭
$1.10
$8.00
Dermata Therapeutics Inc Stock (DRMA) Company Profile
명칭
Dermata Therapeutics Inc
전화
(858)-223-0882
주소
3525 DEL MAR HEIGHTS RD., #322, SAN DIEGO
Compare DRMA vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DRMA
Dermata Therapeutics Inc
|
1.33 | 4.83M | 0 | -7.10M | -8.30M | -5.3059 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dermata Therapeutics Inc 주식(DRMA)의 최신 뉴스
Dermata Therapeutics Warrant (DRMAW) Slides 19.73% as Price Nears Critical Floor at $0.01Dark Pool Volume - newsline.com
DRMA Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost Control Amid Pipeline ProgressQuarterly Financial Update - newsline.com
DRMA Q1 2026 Earnings: Better-than-Expected Loss Reduction Amidst Pipeline Development FocusShare Dilution Risk - newsline.com
DRMA Q1 2026 Earnings: Narrower Loss Surpasses Expectations as Clinical Advances ContinueSlow Growth Warning - newsline.com
Dermata Therapeutics (DRMA) Edges Higher as Stock Tests Key Resistance LevelsVolume Climax - newsline.com
Lixte Biotechnology Holdings, Inc. (LIXTW) Stock Price, News, Quote & History - Yahoo! Finance Canada
DRMA Q1 2026 Earnings: Positive EPS Surprise as Dermata Advances PipelinePreliminary Results - newsline.com
CFO Kyri Van Hoose (DRMA) discloses 9% Dermata ownership in Schedule 13D - Stock Titan
[EFFECT] Dermata Therapeutics, Inc. SEC Filing - Stock Titan
Dermata Therapeutics, Inc. Financial Disclosures & SEC Filings - TradingView
Dermata Therapeutics Warrant (DRMAW) Holds at Penny Level – Key Levels to WatchAI Trade Signals - newsline.com
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf registration - Stock Titan
Dermata Therapeutics (DRMA) Stages Modest Recovery – Support Holds Above $1.28Keltner Channel - The Legal Advocate
Dermata Therapeutics (DRMA) Shares Climb 3.85% as Stock Tests Key Resistance LevelsVolume Breakout Ideas - The Legal Advocate
Dermata Therapeutics Adopts Fourth Amendment to 2021 Omnibus Equity Incentive Plan – Form 8-K Filing Summary - Minichart
Dermata Therapeutics Shareholders Approve Equity Plan and Directors - TipRanks
Dermata (NASDAQ: DRMA) investors approve equity plan expansion and warrant changes - Stock Titan
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
DRMA Q1 2026 Earnings: Narrower Loss Than Expected Bolsters Investor SentimentRevenue Report - Newser
Dermata Therapeutics (NASDAQ: DRMA) files $100M shelf for stock, warrants - Stock Titan
DRMA Q1 2026 Earnings: Narrower-than-Expected Loss Marks Progress for Clinical-Stage BiotechEarnings Yield Spread - The Legal Advocate
Dermata Therapeutics (DRMA) Slides 0.8% as Shares Hover Near Support at $1.18Virgin POC - Newser
Dermata Therapeutics Warrant (DRMAW) Holds at $0.01 as Trading Remains FlatGap Fill Strategy - Newser
Dermata shares rise after USPTO issues patent notice of allowance - MSN
Dermata Therapeutics, Inc.Common Stock (NQ: DRMA - FinancialContent
DRMA Should I Buy - Intellectia AI
Inhibikase Therapeutics, Inc.Common Stock (NQ: IKT - FinancialContent
DRMA Stock Chart | DERMATA THERAPEUTICS INC (NASDAQ:DRMA) - ChartMill
DRMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Dermata Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Dermata Therapeutics (NASDAQ:DRMA) Q1 2026 Earnings: Narrowing Losses and Strategic Pivot to DTC Skincare - ChartMill
Intracoastal-linked holders report 4.99% stake in Dermata (NASDAQ: DRMA) - Stock Titan
Once-weekly Tome mask aims to bring professional skincare home by mid-2026 - Stock Titan
[10-Q] Dermata Therapeutics, Inc. Quarterly Earnings Report - Stock Titan
Dermata Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Dermata (NASDAQ: DRMA) advances DTC pivot in Q1 2026 update - Stock Titan
Dermata Therapeutics Provides Corporate Update and Reports Financial Results for the First Quarter 2026 - newswire.com
TradingKey - TradingKey
What Dermata (DRMAW) flagged as biggest challenges ahead | DRMAW Q3 Earnings: Dermata Warrant Reports No Revenue or Earnings DataCommunity Sell Signals - Newser
Dermata Therapeutics Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Dermata Therapeutics Inc. (DRMA) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
DRMAW Dermata quarterly earnings core metrics remain unavailable as investors await full official operational and financial disclosures.Forward Guidance - newser.com
DRMAW SEC FilingsDermata Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
RBC Capital initiates Dermata Therapeutics stock at outperform By Investing.com - Investing.com South Africa
RBC Capital initiates Dermata Therapeutics stock at outperform - Investing.com
Dermata (DRMA) Stock Valuation | Dermata Therapeutics posts narrower loss, 3.2 pct EPS beatSurprise Factor - Cổng thông tin điện tử tỉnh Lào Cai
Bigger Capital now holds 75,200 shares after sales (NASDAQ: DRMA) - Stock Titan
Dermata (DRMA) Stock Hot Topic (Institutional Selling) 2026-04-20Analyst Consensus - Cổng thông tin điện tử tỉnh Lào Cai
Dermata Therapeutics (NASDAQ: DRMA) seeks approval for warrants and equity plan at 2026 meeting - Stock Titan
Dermata Therapeutics Inc (DRMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Dermata Therapeutics Inc 주식 (DRMA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Bedoya-Toro Munera Maria E | SVP, Regulatory Affairs |
Feb 17 '26 |
Buy |
1.27 |
1,000 |
1,270 |
1,012 |
2.60%
0.94%
자본화:
|
볼륨(24시간):